Studying Suboxone Act
This bill requires the Department of Health and Human Services (HHS) and the Drug Enforcement Administration (DEA) to reevaluate the scheduling of buprenorphine-naloxone combination products (e.g., suboxone) under the Controlled Substances Act. These products are used to treat opioid addictions and are currently schedule III controlled substances. (A schedule III controlled substance is a drug, substance, or chemical that has less potential for abuse than a schedule I or II substance; that has a currently accepted medical use; and that has low or moderate risk of dependence if abused.)
Specifically, the bill requires HHS to review scientific and medical evaluations relating to these products and update its scheduling recommendations accordingly. The DEA must review the recommendations of HHS and make appropriate scheduling changes.
[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4053 Introduced in House (IH)]
<DOC>
118th CONGRESS
1st Session
H. R. 4053
To provide for the review of the scheduling under the Controlled
Substances Act of buprenorphine-naloxone combination products, and for
other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
June 13, 2023
Ms. Kuster (for herself and Mr. Carter of Georgia) introduced the
following bill; which was referred to the Committee on Energy and
Commerce, and in addition to the Committee on the Judiciary, for a
period to be subsequently determined by the Speaker, in each case for
consideration of such provisions as fall within the jurisdiction of the
committee concerned
_______________________________________________________________________
A BILL
To provide for the review of the scheduling under the Controlled
Substances Act of buprenorphine-naloxone combination products, and for
other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Studying Suboxone Act''.
SEC. 2. REVIEWING THE SCHEDULING OF BUPRENORPHINE-NALOXONE COMBINATION
PRODUCTS.
(a) Secretary of HHS.--The Secretary of Health and Human Services
shall--
(1) review and, as appropriate, update the scientific and
medical evaluation conducted under section 201(b) of the
Controlled Substance Act (21 U.S.C. 811(b)) with respect to
buprenorphine-naloxone combination products; and
(2) update, as necessary, the Secretary's scheduling
recommendation under such section with respect to such
products.
(b) Attorney General.--The Attorney General shall--
(1) review the recommendations provided by the Secretary
under subsection (a), and all other relevant data with respect
to the scheduling of buprenorphine-naloxone combination
products;
(2) consider the factors listed in subsection (c) of
section 201 of the Controlled Substance Act (21 U.S.C. 811)
with respect to such products; and
(3) consistent with such section 201, make such scheduling
changes with respect to such products as the Secretary may
determine appropriate.
<all>
Introduced in House
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line